BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15883179)

  • 21. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
    Alastruey-Izquierdo A; Castelli MV; Cuesta I; Monzon A; Cuenca-Estrella M; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1686-9. PubMed ID: 19171801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.
    Chau AS; Chen G; McNicholas PM; Mann PA
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3917-9. PubMed ID: 16966400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
    Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of medium composition on static and cidal activity of amphotericin B, itraconazole, voriconazole, posaconazole and terbinafine against Aspergillus fumigatus: a multicenter study.
    Tortorano AM; Dannaoui E; Meletiadis J; Mallie M; Viviani MA; Piens MA; Rigoni AL; Bastide JM; Grillot R;
    J Chemother; 2002 Jun; 14(3):246-52. PubMed ID: 12120878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology.
    Cafini F; Sevillano D; Alou L; Gómez-Aguado F; Corcuera MT; González N; Guinea J; Prieto J
    Rev Esp Quimioter; 2012 Mar; 25(1):47-55. PubMed ID: 22488542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
    Espinel-Ingroff A; Canton E; Gibbs D; Wang A
    J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.
    Alastruey-Izquierdo A; Cuesta I; Walther G; Cuenca-Estrella M; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3058-60. PubMed ID: 20421405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.
    Bellanger AP; Albert ND; Lewis RE; Walsh TJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7830-2. PubMed ID: 26392499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3.
    Varga I; Sóczó G; Kardos G; Majoros L
    J Antimicrob Chemother; 2008 Jul; 62(1):149-52. PubMed ID: 18390882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella.
    Pastor FJ; Ruíz-Cendoya M; Pujol I; Mayayo E; Sutton DA; Guarro J
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4550-5. PubMed ID: 20805397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of posaconazole and voriconazole in vitro killing against Candida krusei.
    Cantón E; Pemán J; Valentín A; Bosch M; Espinel-Ingroff A; Gobernado M
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):177-81. PubMed ID: 18691842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.
    Oliveira ER; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; Redding SW
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3544-5. PubMed ID: 16048980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
    MacCallum DM; Whyte JA; Odds FC
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3697-701. PubMed ID: 16127042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy.
    Coen M; Bodkin J; Power D; Bubb WA; Himmelreich U; Kuchel PW; Sorrell TC
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4018-26. PubMed ID: 16982786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
    Heyn K; Tredup A; Salvenmoser S; Müller FM
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
    Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
    Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.
    Chamilos G; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2006 Jan; 50(1):96-103. PubMed ID: 16377673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.